Overview

Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis

Status:
Completed

Trial end date:
2018-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this research study to find out if a drug called OctreoScan or DOTATATE can help doctors diagnose people with cardiac sarcoidosis better. OctreoScan and DOTATATE are both approved by the U.S. Food and Drug Administration (FDA) to diagnose certain tumors.

Phase:

N/A

Details

Lead Sponsor:

Marcelo F. Di Carli, MD, FACC

Collaborator:

Mallinckrodt

Treatments:

Somatostatin